Related Experiment Video
Updated: Jan 13, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
4.0K
Left ventricular hypertrophy and renin-angiotensin system blockade
Brett R Cowan1, Alistair A Young
1Centre for Advanced MRI, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland 1142, New Zealand. b.cowan@auckland.ac.nz
Current Hypertension Reports
|May 16, 2009
Summary
Blocking the renin-angiotensin system (RAS) effectively reduces left ventricular hypertrophy (LVH) and associated cardiovascular risk. RAS blockers offer benefits beyond blood pressure reduction, with similar efficacy between ACE inhibitors and ARBs for LVH regression.
Area of Science:
- Cardiology
- Pharmacology
- Physiology
Background:
- The renin-angiotensin system (RAS) regulates blood pressure and fluid balance.
- RAS activation contributes to left ventricular hypertrophy (LVH) and fibrosis.
- LVH is an independent cardiovascular risk factor.
Purpose of the Study:
- To review the role of RAS in LVH.
- To evaluate the efficacy of RAS blockade in preventing and regressing LVH.
- To compare the effectiveness of different RAS-blocking agents.
Main Methods:
- Review of large clinical trials on RAS blockade.
- Analysis of studies comparing ACE inhibitors and ARBs for LVH regression.
Main Results:
- RAS blockade, including ACE inhibitors and ARBs, prevents and regresses LVH.
- RAS blockers provide cardiovascular benefits beyond blood pressure reduction.
- No significant difference in LVH regression efficacy between ACE inhibitors and ARBs was found.
Conclusions:
- RAS blockade is crucial for managing LVH and reducing cardiovascular risk.
- The precise mechanism for additional benefits of RAS blockers beyond BP reduction requires further investigation.
- Both ACE inhibitors and ARBs are effective in regressing LVH.
